Docket No.: PF-0027 US

IN THE CLAIMS

Please amend claims 40 and 52-54, as follows.

For the Examiner's convenience, remaining pending claims 41-51 and 55-60 are also listed below. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

SUB Lon

40. (Once amended.) An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- a) a polynucleotide sequence encoding an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
- b) a polynucleotide sequence encoding a naturally-occurring amino acid sequence which hybridizes under stringent conditions to the full length of a),
- c) a polynucleotide sequence fully complementary along its length to a),
- d) a polynucleotide sequence fully complementary along its length to b), and
- e) a ribonucleotide equivalent of a)-d).
- 41. (Reiterated.) An isolated polynucleotide of claim 40, having a sequence of SEQ ID NO:1.
- 42. (Reiterated.) An isolated polynucleotide of claim 40, having a sequence of SEQ ID NO:3.
- 43. (Reiterated.) An isolated polypeptide encoded by a polynucleotide of claim 40.
- 44. (Reiterated.) An isolated polypeptide of claim 43, having a sequence of SEQ ID NO:2.
- 45. (Reiterated.) An isolated polypeptide of claim 43, having a sequence of SEQ ID NO:4.
- 46. (**Reiterated.**) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 40.
 - 47. (Reiterated.) A cell transformed with a recombinant polynucleotide of claim 46.

Docket No.: PF-0027 US

- 48. (Reiterated.) A method for producing a polypeptide, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 46, and
- b) recovering the polypeptide so expressed.
- 49. (**Reiterated.**) A method of claim 48, wherein the polypeptide has the sequence of SEQ ID NO:2.
- 50. (**Reiterated.**) A method of claim 48, wherein the polypeptide has the sequence of SEQ ID NO:4.
 - 51. (Reiterated.) An isolated antibody which specifically binds to a polypeptide of claim 43.
- 52. (Once amended.) An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - a) a polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3,
 - b) a naturally-occurring polynucleotide sequence which hybridizes under stringent conditions to the full sequence of a),
 - c) a polynucleotide sequence fully complementary along its length to a),
 - d) a polynucleotide sequence fully complementary along its length to b), and
 - e) a ribonucle tide equivalent of a)-d).
- 53. (Once amended.) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 52, the method comprising:
 - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides, said probe comprising a sequence complementary to said target polynucleotide in the sample, and which said probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
 - b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof; wherein the amount of hybridization complex corresponds to the amount of target polynucleotide in the sample.



54. (Once amended.) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 52, the method comprising:

Sub Sub (a)

amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof; wherein the amount of amplified polynucleotide corresponds to the amount of target polynucleotide in the sample.

- 55. (**Reiterated.**) A composition comprising a polypeptide of claim 43 and an acceptable excipient.
- 56. (**Reiterated.**) A composition of claim 55, wherein the polypeptide has the sequence of SEQ ID NO:2.
- 57. (**Reiterated.**) A composition of claim 55, wherein the polypeptide has the sequence of SEQ ID NO:4.
- 58. (**Reiterated.**) A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 43, the method comprising:
 - a) exposing a sample comprising a polypeptide of claim 43 to a compound, and
 - b) detecting agonist activity in the sample.
- 59. (**Reiterated.**) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 43, the method comprising:
 - a) exposing a sample comprising a polypeptide of claim 43 to a compound, and
 - b) detecting antagonist activity in the sample.
- 60. (**Reiterated.**) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 52, the method comprising:
 - exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,



b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.